GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NexGel Inc (NAS:NXGL) » Definitions » Shares Outstanding (EOP)

NexGel (NexGel) Shares Outstanding (EOP) : 6.23 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is NexGel Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. NexGel's shares outstanding for the quarter that ended in Mar. 2024 was 6.23 Mil.

NexGel's quarterly shares outstanding increased from Dec. 2023 (5.74 Mil) to Mar. 2024 (6.23 Mil). It means NexGel issued new shares from Dec. 2023 to Mar. 2024 .

NexGel's annual shares outstanding increased from Dec. 2022 (5.58 Mil) to Dec. 2023 (5.74 Mil). It means NexGel issued new shares from Dec. 2022 to Dec. 2023 .


NexGel Shares Outstanding (EOP) Historical Data

The historical data trend for NexGel's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexGel Shares Outstanding (EOP) Chart

NexGel Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial 5.57 2.25 5.57 5.58 5.74

NexGel Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.61 5.70 5.72 5.74 6.23

Competitive Comparison of NexGel's Shares Outstanding (EOP)

For the Medical Instruments & Supplies subindustry, NexGel's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NexGel's Shares Outstanding (EOP) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NexGel's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where NexGel's Shares Outstanding (EOP) falls into.



NexGel Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


NexGel  (NAS:NXGL) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


NexGel Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of NexGel's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


NexGel (NexGel) Business Description

Traded in Other Exchanges
N/A
Address
2150 Cabot Boulevard West, Suite B, Langhorne, PA, USA, 19047
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies. The company recognizes revenue from contract manufacturing.
Executives
Steven Mark Glassman director 99 LEWIS POINT ROAD, FAIR HAVEN NJ 07704
Nachum Stein director QUADRAX CORP, 618 MAIN ST PO BOX 1001, WEST WARWICK RI 02893
Scott Robert Henry director 34A ATLANTIC AVE., COHASSET MA 02025
David Stefansky director 850 THIRD AVENUE, SUITE 1801, NEW YORK NY 10022
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Yaakov Spinrad director 3450 OAKTON ST, SKOKIE IL 60076
Drapczuk Adam E Iii officer: Chief Financial Officer 6 OAKMONT TERRACE, EAST WINDSOR NJ 08520
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Bezalel Partners Llc 10 percent owner C/O KRIEGER & PRAGER LLP, 39 BROADWAY, STE 920, NEW YORK NY 10006
Adam R. Levy officer: CEO and President 2 AVENUE OF TWO RIVER SOUTH, RUMSON NJ 07760
David Ian Johnson director, officer: Chief Executive Officer C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Adynxx, Inc. 10 percent owner 100 PINE ST., STE. 500, SAN FRANCISCO CA 94111